Cell Signaling Technology Logo
1% for the planet logo

Citrullinated Histone H3 (Arg17) (E4O3F) & CO-0201-647 SignalStar® Oligo-Antibody Pair #51611

Filter:
  • IHC

Order Information # 51611

This product is not sold separately. Please see the SignalStar® Multiplex IHC Panel Builder Tool for ordering information.

    Product Information

    Product Usage Information

    Application Dilution
    SignalStar™ Leica Bond 1:50 - 1:200
    SignalStar™ Manual 1:50 - 1:200

    Storage

    SignalStar conjugates are supplied in PBS (pH 7.2), less than 0.1% sodium azide, 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Complementary oligos are supplied in nuclease-free water. Store at -20°C. Do not aliquot the antibody. All components in this kit are stable for at least 12 months when stored at the recommended temperature.

    Product Description

    SignalStar multiplex immunohistochemistry (IHC) is an advanced technology for labeling multiple proteins simultaneously in tissue samples using specific primary antibodies and fluorescent detection reagents. This technology offers accuracy and reliability in visualizing and analyzing protein expression while maintaining spatial context and tissue architecture.

    SignalStar Oligo-Antibody Pairs are compatible with the SignalStar Multiplex IHC Buffer Kits for use in fluorescent multiplex imaging experiments. This product includes the oligo-conjugated antibodies and complementary oligos required for labeling your target protein on up to 10 slides. SignalStar Multiplex IHC Buffer Kits are required to amplify and image the target signal. Multiple oligo-antibody pairs can be conveniently combined into a multiplex panel using the SignalStar Multiplex IHC Panel Builder. SignalStar Multiplex IHC Kits & Reagents are not compatible with all of Cell Signaling Technology® products and protocols that are recommended for use in immunohistochemical assays.

    Protocol

    Specificity / Sensitivity

    Citrullinated Histone H3 (Arg17) (E4O3F) Rabbit mAb (SignalStar® Conjugate 0201) recognizes histone H3 citrullinated at residue Arg17. This antibody may also recognize histone H3 citrullinated at residue Arg26, but does not cross-react with any other known citrullinated or methylated arginine residues on histone H3. This antibody may detect a band of unknown identity at 38 kDa.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the amino terminus of histone H3 in which Arg17 is citrullinated.

    Background

    The nucleosome, made up of four core histone proteins (H2A, H2B, H3, and H4), is the primary building block of chromatin. Histone post-translational modifications, such as methylation, acetylation, ubiquitination, and citrullination, influence chromatin accessibility and regulate gene expression (1). Histone citrullination is carried out by protein arginine deiminases (PADs), which convert positively charged arginine residues into neutral citrulline (2). Histone citrullination affects the binding of histone reader proteins to chromatin, and it is associated with both transcriptional activation and repression (3-5). Histone citrullination is also a major marker for NETosis, which is a programmed cell death mechanism carried out by neutrophils (6). Deregulation of NETosis is associated with multiple autoimmune diseases, including rheumatoid arthritis (RA) and lupus (7,8). Histone hypercitrullination via PAD4 may also play a role in the progression of various cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), lung cancer, and hepatocellular carcinoma (HCC) (9-12).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStar is a registered trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 10,781,477, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.